Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
<p>Abstract</p> <p>Background</p> <p>Hereditary cancers account for 5–10% of cancers. In this study <it>BRCA1</it>, <it>BRCA2 </it>and <it>CHEK2</it>*(1100delC) were analyzed for mutations in 91 HBOC/HBC/HOC families and early onset b...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-08-01
|
Series: | Hereditary Cancer in Clinical Practice |
Online Access: | http://www.hccpjournal.com/content/7/1/13 |
id |
doaj-15c5aeb7b5a34b3696c920e9be875bc8 |
---|---|
record_format |
Article |
spelling |
doaj-15c5aeb7b5a34b3696c920e9be875bc82020-11-24T23:08:23ZengBMCHereditary Cancer in Clinical Practice1897-42872009-08-01711310.1186/1897-4287-7-13Molecular genetics analysis of hereditary breast and ovarian cancer patients in IndiaSoumittra NagasamyMeenakumari BalaiahParija TithiSridevi VeluswamiNancy Karunakaran NSwaminathan RajaramanRajalekshmy Kamalalayam RMajhi UrmilaRajkumar Thangarajan<p>Abstract</p> <p>Background</p> <p>Hereditary cancers account for 5–10% of cancers. In this study <it>BRCA1</it>, <it>BRCA2 </it>and <it>CHEK2</it>*(1100delC) were analyzed for mutations in 91 HBOC/HBC/HOC families and early onset breast and early onset ovarian cancer cases.</p> <p>Methods</p> <p>PCR-DHPLC was used for mutation screening followed by DNA sequencing for identification and confirmation of mutations. Kaplan-Meier survival probabilities were computed for five-year survival data on Breast and Ovarian cancer cases separately, and differences were tested using the Log-rank test.</p> <p>Results</p> <p>Fifteen (16%) pathogenic mutations (12 in <it>BRCA1 </it>and 3 in <it>BRCA2</it>), of which six were novel <it>BRCA1 </it>mutations were identified. None of the cases showed <it>CHEK2</it>*1100delC mutation. Many reported polymorphisms in the exonic and intronic regions of <it>BRCA1 </it>and <it>BRCA2 </it>were also seen. The mutation status and the polymorphisms were analyzed for association with the clinico-pathological features like age, stage, grade, histology, disease status, survival (overall and disease free) and with prognostic molecular markers (ER, PR, c-erbB2 and p53).</p> <p>Conclusion</p> <p>The stage of the disease at diagnosis was the only statistically significant (p < 0.0035) prognostic parameter. The mutation frequency and the polymorphisms were similar to reports on other ethnic populations. The lack of association between the clinico-pathological variables, mutation status and the disease status is likely to be due to the small numbers.</p> http://www.hccpjournal.com/content/7/1/13 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Soumittra Nagasamy Meenakumari Balaiah Parija Tithi Sridevi Veluswami Nancy Karunakaran N Swaminathan Rajaraman Rajalekshmy Kamalalayam R Majhi Urmila Rajkumar Thangarajan |
spellingShingle |
Soumittra Nagasamy Meenakumari Balaiah Parija Tithi Sridevi Veluswami Nancy Karunakaran N Swaminathan Rajaraman Rajalekshmy Kamalalayam R Majhi Urmila Rajkumar Thangarajan Molecular genetics analysis of hereditary breast and ovarian cancer patients in India Hereditary Cancer in Clinical Practice |
author_facet |
Soumittra Nagasamy Meenakumari Balaiah Parija Tithi Sridevi Veluswami Nancy Karunakaran N Swaminathan Rajaraman Rajalekshmy Kamalalayam R Majhi Urmila Rajkumar Thangarajan |
author_sort |
Soumittra Nagasamy |
title |
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India |
title_short |
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India |
title_full |
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India |
title_fullStr |
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India |
title_full_unstemmed |
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India |
title_sort |
molecular genetics analysis of hereditary breast and ovarian cancer patients in india |
publisher |
BMC |
series |
Hereditary Cancer in Clinical Practice |
issn |
1897-4287 |
publishDate |
2009-08-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Hereditary cancers account for 5–10% of cancers. In this study <it>BRCA1</it>, <it>BRCA2 </it>and <it>CHEK2</it>*(1100delC) were analyzed for mutations in 91 HBOC/HBC/HOC families and early onset breast and early onset ovarian cancer cases.</p> <p>Methods</p> <p>PCR-DHPLC was used for mutation screening followed by DNA sequencing for identification and confirmation of mutations. Kaplan-Meier survival probabilities were computed for five-year survival data on Breast and Ovarian cancer cases separately, and differences were tested using the Log-rank test.</p> <p>Results</p> <p>Fifteen (16%) pathogenic mutations (12 in <it>BRCA1 </it>and 3 in <it>BRCA2</it>), of which six were novel <it>BRCA1 </it>mutations were identified. None of the cases showed <it>CHEK2</it>*1100delC mutation. Many reported polymorphisms in the exonic and intronic regions of <it>BRCA1 </it>and <it>BRCA2 </it>were also seen. The mutation status and the polymorphisms were analyzed for association with the clinico-pathological features like age, stage, grade, histology, disease status, survival (overall and disease free) and with prognostic molecular markers (ER, PR, c-erbB2 and p53).</p> <p>Conclusion</p> <p>The stage of the disease at diagnosis was the only statistically significant (p < 0.0035) prognostic parameter. The mutation frequency and the polymorphisms were similar to reports on other ethnic populations. The lack of association between the clinico-pathological variables, mutation status and the disease status is likely to be due to the small numbers.</p> |
url |
http://www.hccpjournal.com/content/7/1/13 |
work_keys_str_mv |
AT soumittranagasamy moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia AT meenakumaribalaiah moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia AT parijatithi moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia AT srideviveluswami moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia AT nancykarunakarann moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia AT swaminathanrajaraman moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia AT rajalekshmykamalalayamr moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia AT majhiurmila moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia AT rajkumarthangarajan moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia |
_version_ |
1725614481523867648 |